European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - ibandronic acid - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - drugs for treatment of bone diseases - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. treatment of tumour-induced hypercalcaemia with or without metastases. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - levetiracetam - epilepsy - antiepileptics, - matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - venlafaxine hydrochloride - prolonged-release capsule, hard - 75 milligram(s) - other antidepressants; venlafaxine

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - venlafaxine hydrochloride - prolonged-release capsule, hard - 150 milligram(s) - other antidepressants; venlafaxine

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole mylan pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.aripiprazole mylan pharma is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole mylan pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmathen s.a. - olanzapine - tablets orodispersible - 5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmathen s.a. - olanzapine - tablets orodispersible - 10mg